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Abstract
Background/Purpose: Radiotherapy (RT) volumes for anal cancer are large and of moderate
complexity when organs at risk (OAR) such as testis, small bowel and bladder are at least partially
to be shielded. Volumetric intensity modulated arc therapy (VMAT) might provide OAR-shielding
comparable to step-and-shoot intensity modulated radiotherapy (IMRT) for this tumor entity with
better treatment efficiency.
Materials and methods: Based on treatment planning CTs of 8 patients, we compared dose
distributions, comformality index (CI), homogeneity index (HI), number of monitor units (MU) and
treatment time (TTT) for plans generated for VMAT, 3D-CRT and step-and-shoot-IMRT
(optimized based on Pencil Beam (PB) or Monte Carlo (MC) dose calculation) for typical anal
cancer planning target volumes (PTV) including inguinal lymph nodes as usually treated during the
first phase (0-36 Gy) of a shrinking field regimen.
Results: With values of 1.33 ± 0.21/1.26 ± 0.05/1.3 ± 0.02 and 1.39 ± 0.09, the CI's for IMRT (PB-
Corvus/PB-Hyperion/MC-Hyperion) and VMAT are better than for 3D-CRT with 2.00 ± 0.16. The
HI's for the prescribed dose (HI36) for 3D-CRT were 1.06 ± 0.01 and 1.11 ± 0.02 for VMAT,
respectively and 1.15 ± 0.02/1.10 ± 0.02/1.11 ± 0.08 for IMRT (PB-Corvus/PB-Hyperion/MC-
Hyperion). Mean TTT and MU's for 3D-CRT is 220s/225 ± 11MU and for IMRT (PB-Corvus/PB-
Hyperion/MC-Hyperion) is 575s/1260 ± 172MU, 570s/477 ± 84MU and 610s748 ± 193MU while
TTT and MU for two-arc-VMAT is 290s/268 ± 19MU.
Conclusion: VMAT provides treatment plans with high conformity and homogeneity equivalent
to step-and-shoot-IMRT for this mono-concave treatment volume. Short treatment delivery time
and low primary MU are the most important advantages.
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Introduction
Coverage of large planning target volumes (PTV) as they
are treated during the initial part of the protocols for anal
cancer is difficult because protection of critical organs is
important for the patient's quality of life (QOL) [1]. Until
recently, the standard approach has been three dimen-
sional conformal radiotherapy (3D-CRT), typically using
a 4-field box technique [2]. The target volume for anal
cancer is currently actively being discussed and a consen-
sus document has recently been published by the RTOG
[3]. It is, however, not a consequence of specific clinical
data but the result of a highly subjective approach (super-
position of targets drawn by several individuals) and
issues such as vaginal sparing still require cautious evalu-
ation. The PTV therefore still ususally comprises primary
tumor and lower external and internal iliac lymph nodes.
Medial inguinal lymph nodes are usually treated up to at
least 30.6-36 Gy [4,5] and in case of involvement higher
doses are required (50.4-54 Gy). Treating inguinal lymph
nodes and pelvic lymph nodes simultaneously leads to a
mean PTV size of more than 2.750 cm3 as exemplified in
figure 1 and such relatively large PTVs are still considered
appropriate in recent reviews [6]. Previous studies showed
that IMRT provides PTV coverage similar to conventional
techniques and at the same time efficiently spares OAR
[7]. On the downside, however, IMRT resulted in longer
treatment time and a higher number of monitor units
(MU). While step-and-shoot IMRT has become more effi-
cient recently [8-10] rotational modulated therapy may be
another approach to improve these parameters [11,12].
Volumetric modulated arc therapy (VMAT) is based on
the intensity modulated arc therapy (IMAT) paradigm,
first described by Yu et. al [13,14]. The basic IMAT idea is
to segment on calculated fluences, VMAT on the other
hand segments on given structures. Several research
groups developed their own IMAT solutions in order to
study and exploit its potential for the reduction of treat-
ment time and MU while increasing the number of inci-
dent beam directions [15-19], with large target volumes
such as encountered with whole abdominopelvic radio-
therapy (WAPRT) being particularly in the focus of the
group from Ghent [20,21].
Only recently commercial treatment planning systems
(TPS) were released for modulated arc therapy. Otto intro-
duced a single-arc VMAT approach [22] that formed the
basis for RapidArc© (Varian Medical Systems, USA) that in
its first clinical commercial implementation was then
evaluated by Cozzi et. al[23] and Palma et. al [16].
ERGO++ (Elekta, Sweden) has been released in parallel as
a commercial VMAT system and was evaluated in this
study. To provide comprehensive data, VMAT was com-
pared with a complex 3D-CRT technique (6 fields) and
step-and-shoot IMRT including Monte Carlo and Pencil
Beam calculation. Several strategies (single and dual rota-
tions) were computed, and analysed with regard to dose-
volume-histograms (DVH), homogeneity, conformity,
exposure of OAR and treatment efficiency (treatment time
and monitor units).
Methods and materials
Patient anatomy
Eight CT datasets of patients treated at our department for
anal cancer were the basis for this study. The PTV was typ-
ical for the initial treatment series including the primary
tumor, pelvic and inguinal lymph nodes (figure 1). It is to
be treated at daily doses of 1.8 Gy to a cumulative dose of
36 Gy. In patients without involved inguinal lymph
nodes, the PTV would then be reduced to a typical pelvic
PTV without coverage of inguinal lymph nodes. Finally, a
boost would be delivered to the primary tumor, its dose
depending on tumor size.
Since the initial PTV used in all patients was the most
complex one, evaluation of VMAT is only done in this
context. Bladder, small intestine, gonads and femoral
heads were contoured as OAR. A wedge-shaped anterior
auxiliary structure was generated to facilitate the planning
process.
Treatment planning systems
3D-CRT (Masterplan)
3D-CRT-plans were generated with Masterplan 3.1
(Nucletron, The Netherlands). The field geometry con-
sisted of 6 fields as suggested by Götz and Kiricuta [24]. A
standard 4 field box treated at an energy of 23 MV and
beam angles of 0/87/180/273 degrees was supplemented
by 2 oblique auxiliary fields (energy 6 MV) from 30 and
Axial CT for 3D-CRT with PTV and 6 beams Figure 1
Axial CT for 3D-CRT with PTV and 6 beams.Radiation Oncology 2009, 4:48 http://www.ro-journal.com/content/4/1/48
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330 degrees, both with 30 degree wedges (figure 1). These
additional beams cover the inguinal extensions of the PTV
in the anterior/lateral direction. Dose is calculated based
on a pencil beam (PB) algorithm.
IMRT Treatment Planning
The primary beam setup for the step-and-shoot approach
consisted of 9 isotropic nonopposing coplanar beams,
both for treatment plans generated with Corvus and
Hyperion.
IMRT (Pencil Beam, Corvus)
Corvus 6.3 (Best Nomos, USA) is a fully inverse treatment
planning system that uses a simulated annealing algo-
rithm for the beamlet optimization process [25]. Dose cal-
culation is based on a PB algorithm.
IMRT (Pencil Beam/Monte Carlo, Hyperion)
Hyperion (University of Tuebingen, Germany [26]) has
two major innovative features: evidence-based biological
modelling and X-ray voxel-based Monte Carlo (XVMC)
dose computation including multiple photon transport,
electron history repetition and continuous boundary
crossing used during optimization and final calculation
[27,28]. The system therefore represents several recent
advances in IMRT planning. To evaluate the effect of MC
dose calculation and optimization we generated plans
both based on the PB as well as on the MC algorithm.
VMAT (ERGO++)
ERGO++ 1.7.1 (3D Line Medical Systems/Elekta) uses a
PB algorithm for dose calculation. ERGO++ offers the pos-
sibility to adapt the multi-leaf-collimator (MLC) dynami-
cally to the target structure during the rotation. Dose rate,
gantry speed and the collimator angle can be modified
during the rotation. For our analysis, however, we used a
fixed collimator angle since preliminary studies did not
suggest an additional gain of optimized collimator angle
for the PTV geometry studied. The starting point of the
planning/optimization process is the definition of differ-
ent arrangements of the static control points which divide
the arcs into subarcs and the initial manual MLC adapta-
tion to the target volume. The arc modulation optimiza-
tion algorithm AMOA computes the weighting of each
subarc, depending on dose constraints for PTV and each
OAR, and consequently defines the dose rate/MU-number
for each subarc. Afterwards the sequencer converts the
control points into optimized arcs by using predefined
rules.
First we analysed different single-rotation paradigms and
a dual-rotation approach on the basis of a typical patient/
PTV geometry. The single-arc strategies were: one 360°
rotation conforming the collimator to the PTV with
shielding of the auxiliary structure when it is in front of
the PTV ('1RotiFo') and one 360° rotation on the PTV
with full shielding of the auxiliary structure
('1RotALLW').
The dual-rotation strategy ('2Rot') used two  rotations
with a starting angle of 181° and a stop angle of 179°
each (total of 358°/rotation). These two arcs are subdi-
vided into 72 subarcs for each rotation which results in
one control point every 5 degrees. The first rotation
treated the whole PTV-horns without sparing any OAR
(figure 2). The second rotation around the patient treated
the PTV with permanent shielding of the auxiliary struc-
ture located between the anterior/lateral PTV-bulges (fig-
ure 3) with a margin of 5 mm between the PTV projection
and the leaf edges. After this initial evaluation step, the
approach with the best overall plan quality (the dual-rota-
tion strategy) was evaluated for all 8 treatment planning
CTs.
Treatment devices
IMRT, VMAT and 3D-CRT plans were compted for and
delivered with an Elekta Synergy® linear accelerator with
an energy of 6 MV and a dose rate of 600 MU per minute
(MU/min). 3D-CRT, step-and-shoot IMRT plans and
VMAT plans were delivered through the MOSAIQ record-
and-verify (R&V) system V1.5 (IMPAC Medical Systems
Inc./Elekta) with VMAT plans delivered through the most
recent release of the console software desktop (V7.0.1).
Plan comparison
We compared the calculated dose distributions of all four
planning systems for sagittal, coronal and lateral planes.
The selected patient cases from our database including all
contours for OAR and PTV were identical for every plan-
ning system. Specifically, DVH parameters such as mini-
mal, mean and maximal dose in the PTV and the OAR's as
well as fractional exposure of non-PTV normal tissue was
evaluated. Treatment efficiency was quantified by measur-
ing/calculating total treatment time (TTT) and MU (beam-
on-time plus time for necessary gantry movements).
Finally, we calculated the homogeneity index (HI) and a
modified conformity index (CI) which are objective val-
ues to describe how well the dose distribution conforms
to the shape of a radiosurgical target [29]. The CI was
modified to accommodate the fact, that we prescribed
dose to the median dose level in the PTV, thus invalidat-
ing the classical definition of CI. We therefore defined CI
as follows:
CI
V
V
=
D99%
PTV
(1)Radiation Oncology 2009, 4:48 http://www.ro-journal.com/content/4/1/48
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with  VD99% describing the total volume in cm3 which
receives the effective minimal target dose (Dose encom-
passing 99% of the PTV) and VPTV being the target volume
in cm3. This definition of CI has the advantage that the
value for the minimal dose applied to the target character-
izes CI which is in the spirit of the original definition by
RTOG. HI is defined according to the RTOG guidelines as
follows [30]:
with Dmax being the maximum dose in the treatment plan
and Dprese being the prescription dose.
Results
Evaluation of different VMAT strategies
Figure 4 shows axial, sagittal and coronal dose distribu-
tions (DD) for one selected patient generated by the three
different VMAT strategies. The DD differ with regard to
OAR sparing between the anterior inguinal PTV-exten-
sions, the dose gradient in non-PTV normal tissue, as well
as in conformity and homogeneity (figure 4). The '2Rot'
strategy provides the best conformity and homogeneity
but also the highest dose exposure to the region between
the inguinal PTV extensions (maximum of 28.8 Gy) and
requires the longest treatment time by using 2 rotations.
In contrast, '1RotALLW' creates a steeper dose gradient in
the normal tissue encompassed by the PTV and thus better
HI
D
D
=
max
presc
(2)
Two discrete steps during the first rotation without shielding of OAR Figure 2
Two discrete steps during the first rotation without shielding of OAR.
Three discrete steps during the second rotation with shielding Figure 3
Three discrete steps during the second rotation with shielding.Radiation Oncology 2009, 4:48 http://www.ro-journal.com/content/4/1/48
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protects the anterior OARs (maximum of only 18 Gy). It
also exposes non-PTV tissue to lower integral doses and
TTT is significantly shorter. Overall conformity and
homogeneity, however, are somewhat inferior due to less
modulation during just one rotation. The third strategy,
'1RotiFo', represents a mixed solution with intermediate
conformity, using only one rotation but providing dose
homogeneity similar to what is achieved with the '2Rot'
approach, less dose to the OARs but the highest integral
dose to non-PTV tissue.
DVH analysis (figure 5) showed best PTV coverage for
'2Rot' with the highest D99% and the smallest volume
exposed to high doses. '1RotALLW' was inferior regarding
PTV coverage and homogeneity while '1RotiFo' showed
PTV coverage similar to dual-rotation VMAT.
These differences as parametrized by using CI and HI and
in addition the differences in dose exposure to fractional
volumes are displayed in table 1.
Although treatment time for the 2-rotation strategy was
almost double that of the single-rotation approaches in
this example, further preliminary studies showed that this
particular case marked the upper limit of the treatment
times and that on average shorter treatment times could
be expected also with the 2-rotation approach. Since this
technique provided the best conformity and homogeneity
we chose it as the benchmark for the following compari-
son of VMAT with 3D-CRT and fixed beam IMRT.
Comparison of VMAT and other techniques
Figure 6 shows the dose display for all treatment modali-
ties for a typical patient with the PTV delineated in trans-
parent red. The VMAT DD's were already shown in figure
4. For all treatment techniques the IRCU50 prescription
guidelines (homogeneity -5% and +7% prescription dose
PD) were aimed for but minor deviations had to be
accepted as it is usually the case with modulated RT when
a realistic treatment plan complexity (number of seg-
ments/rotations) for a treatment plan efficiency that is
clinically applicable is used. Using our specific treatmtent
plan normalization to 50% volume and 50% PD [31],
minor compromises were made on the side of both cover-
age and homogeneity, as reported in table 1. The DD for
3D-CRT shows good homogeneity (no hot or cold spots)
but the largest region of non-PTV tissue exposed to high
doses. The IMRT Hyperion DD are highly conformal but
less homogeneous than 3D-CRT or VMAT "2Rot". Hyper-
ion provides the option to perform PB as well as MC
based optimization/calculation. In PB-based calculations,
lateral scattering and linear attenuation of x-rays in the
Dose distributions for different VMAT strategies Figure 4
Dose distributions for different VMAT strategies. Best homogeneity for 2Rot and best conformity and dose sparing in 
normal tissue for 1RotALLW.
 2Rot 
1RotiFo 
1RotALLWRadiation Oncology 2009, 4:48 http://www.ro-journal.com/content/4/1/48
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patient are not modelled correctly. As consequence, the
PB dose distributions look much smoother and subjec-
tively better than MCPB based calculation showing more
homogeneous dose distributions than MC. While MC-
based plans are more precisely reflecting true absorbed
dose, PB was calculated to provide comparison data on
the same calculation basis as for the other systems. IMRT
Corvus DD has the worst homogeneity and less conform-
ity. Best anterior OAR sparing is performed by IMRT
Hyperion.
For DVH generation and comparison (figure 7), all treat-
ment plans were normalized to 36 Gy to the median dose
level in the PTV. The highest minimal dose and the lowest
maximal dose for the PTV was achieved by 3D-CRT, fol-
lowed by VMAT "2Rot", IMRT Hyperion and finally IMRT
OAR and PTV DVH's of the VMAT strategies Figure 5
OAR and PTV DVH's of the VMAT strategies. The VMAT '2Rot' (dotted line, best homogeneity), VMAT '1RotiFo' (solid 
line) and VMAT '1RotALLW' (dashed line, best dose sparing in OAR and tissue-PTV).
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Table 1: DVH parameters for the different VMAT techniques
2Rot 1Rot iFo 1RotALLW
HI 1.1 1.1 1.15
CI 1.46 1.54 1.49
MU 287 293 348
TT 370s 185s 188s
VTissue 10% PD 13414 cm3 ≡ 38.98% 13643 cm3 ≡ 39.6% 12456 cm3 ≡ 36.2%
VTissue 30% PD 10345 cm3 ≡ 30.1% 10635 cm3 ≡ 30.9% 8741 cm3 ≡ 25.4%
VTissue 50% PD 7571 cm3 ≡ 22.0% 8157 cm3 ≡ 23.7% 5321 cm3 ≡ 15.5%
VTissue 70% PD 4089 cm3 ≡ 11.9% 4735 cm3 ≡ 13.8% 2727 cm3 ≡ 7.9%
VTissue 95% PD 430 cm3 ≡ 1.2% 370 cm3 ≡ 1.1% 0 cm3 ≡ 0%
D95% Vol PTV 33.84 Gy ≡ 94% 33.48 Gy ≡ 93% 32.4 Gy ≡ 90%
D95% Vol Tissue 0.75 Gy ≡ 2.09% 0.8 Gy ≡ 2.22% 0.02 Gy ≡ 0.06%Radiation Oncology 2009, 4:48 http://www.ro-journal.com/content/4/1/48
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Corvus. The best non-PTV tissue sparing was performed
by IMRT Hyperion, the worst by 3D-CRT. Analysing the
DVH for bladder, the lowest dose exposure to bladder was
acheived by IMRT Hyperion, followed by VMAT "2Rot"
and almost no sparing with 3D-CRT. The DVH's for small
intestine show no big differenes.
Figure 8 and table 2 indicate the best HI but the worst CI
for 3D-CRT. VMAT and IMRT are similar regarding CI and
HI, consistently for all individual plans. With values of
1.07 to 1.15 for HI (table 2) all planning systems are
within the RTOG recommendations [30].
Axial, coronal and sagittal dose distribution for OTP (3D-CRT), IMRT Hyperion with MC, IMRT Hyperion with PB and Corvus  with PB (top to bottom) Figure 6
Axial, coronal and sagittal dose distribution for OTP (3D-CRT), IMRT Hyperion with MC, IMRT Hyperion with 
PB and Corvus with PB (top to bottom).Radiation Oncology 2009, 4:48 http://www.ro-journal.com/content/4/1/48
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As parametrized by MU-number and TTT (table 2), 3D-
CRT and VMAT "2Rot" are the fastest/most efficient tech-
niques. TTT is 50% shorter than for IMRT and mean MU-
number is reduced by more than 70%.
Discussion
VMAT combines the advantages of conventional 3D-radi-
otherapy (3D-CRT) with its fast delivery and low number
of monitor units (MU) and the advantages of IMRT with
the conformal dose distribution (DD) and the reduced
dose to critical OAR in when target volumes are irradiated
according to recently published recommendations [6].
The benefit of IMRT over 3D-CRT regarding high dose
conformity and OAR sparing for pelvic tumors and specif-
ically anal cancer was shown earlier [2,7,32-36]. Chen et
al. compared IMRT and 3D-CRT (AP-PA photons with en-
face electrons) for anal cancer and they could show that
while PTV coverage of IMRT and 3D-CRT were compara-
ble, surrounding OAR received less dose exposure with
IMRT [7]. Mundt et al and Roeske et al. analysed whole
pelvic radiation for gynecologic malignancies and con-
cluded that IMRT reduces the volume of normal tissue
receiving high doses [32] resulting in fewer small bowel
complications [35] while retaining PTV coverage. Toxicity
and clinical outcome of IMRT for anal cancer was ana-
lysed by Milano et al [34]. The group could reduce the
radiation dose to normal structures with IMRT and
reported a reduction of acute and late toxicities. On the
other hand, the increased delivery time allows the repair
of sublethal damage (SLD) in tumour cells and might
reduce the biological effect [37,38]. Though the relevance
of this issue is unclear with TTT having been reduced since
the introduction of IMRT and initial reports on dose-pro-
traction effects [39-41], shortening treatment times to ~5
min will completely obviate this discussion.
Since we studied a PTV paradigm with a moderate cranial
extension we did not explicitly evaluate bone marrow
sparing in the iliac crest, which is in line with the data of
Menkarios et al., who had extensively discussed the merit
of modulated treatment for anal cancer [2]. They had
stressed the technical feasibility and potential benefit of
IMRT with regard to bone marrow sparing for PTVs with a
high upper limit. Their data, however also shows that for
targets with a low upper limit, such as ours, there is no rel-
evant exposure of the iliac crest with any of the studied
techniques.
In our evaluation, VMAT, IMRT and 3D-CRT provide
almost the same dose coverage in the target but 3D-CRT
exposes the surrounding tissue and consequently the OAR
DVH comparison of VMAT '2 Rot', IMRT and 3D-CRT Figure 7
DVH comparison of VMAT '2 Rot', IMRT and 3D-CRT.
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to much higher doses. Sparing of bladder and possibly
small bowel between the inguinal lymph nodes included
in the PTV, however, is not adequately achieved by 3D-
CRT.
So far, commercial planning systems for IMAT/VMAT are
a not widely spread and initial data were collected with
investigational systems, such as those of the groups from
Beamount Hospital, Ghent and Vancouver. These initial
reports suggested that VMAT may improve the effiency of
modulated radiation therapy. Duthoy et al. reported on
the feasability of whole abdominopelvic RT using IMAT
with a low number of MU's (444 MU) [20] and also
reported short treatment times (6.3 minutes) for the treat-
ment of rectal cancer [21].
Both single- and multiple-arc approaches are currently
being established clinically for VMAT, showing similar
potential for reducing treatment time when plans of equal
quality are generated [40]. Clinical implementation of
these techniques has also prompted reports on appropri-
ate QA paradigms [41,42].
A single-arc therapy approach was devised by Wang et al
The group used a commercial planning system to opti-
mize the intensity profiles of a treatment plan with 36
equi-spaced static beam angles and exported these profiles
to an investigational sequencing algorithm to generate a
single-arc plan, recalculated with a MC algorithm that was
also developed in-house. They investigated multiple tar-
get locations and found that their arc-modulation-radia-
HI and CI for all individual patients Figure 8
HI and CI for all individual patients.
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Table 2: Mean TT, MU-number, CI and HI for the three planning systems
3D-CRT VMAT '2Rot' IMRT (MC Hyperion) IMRT (PB Hyperion) IMRT (PB Corvus)
HI 1.06 ± 0.02 1.11 ± 0.02 1.11 ± 0.08 1.10 ± 0.02 1.15 ± 0.03
CI 2.00 ± 0.16 1.39 ± 0.09 1.30 ± 0.02 1.26 ± 0.05 1.33 ± 0.21
MU 225 ± 11 268 ± 19 748 ± 193 477 ± 84 1260 ± 172
TT 220s 290s 610s 570s 575s
VTissue 10% PD 10739 cm3 ≡ 48.8% 10463 cm3 ≡ 47.6% 10806 cm3 ≡ 48.1% 10347 cm3 ≡ 46.0% 10591 cm3 ≡ 47.5%
VTissue 30% PD 8187 cm3 ≡ 37.3% 7674 cm3 ≡ 34.9% 7593 cm3 ≡ 33.8% 7199 cm3 ≡ 32.0% 7874 cm3 ≡ 35.3%
VTissue 50% PD 6052 cm3 ≡ 27.6% 5089 cm3 ≡ 23.1% 4203 cm3 ≡ 18.7% 3971 cm3 ≡ 17.7% 5186 cm3 ≡ 23.2%
VTissue 70% PD 3428 cm3 ≡ 15.6% 2734 cm3 ≡ 12.4% 1939 cm3 ≡ 8.6% 1933 cm3 ≡ 8.6% 2612 cm3 ≡ 11.7%
VTissue 95% PD 982 cm3 ≡ 4.5% 208 cm3 ≡ 0.9% 14 cm3 ≡ 0.0% 0 cm3 ≡ 0.0% 53 cm3 ≡ 0.2%
D95% Vol Tissue 1.97 Gy ≡ 5.46% 0.75 Gy ≡ 2.09% 0.35 Gy ≡ 0.98% 0.31 Gy ≡ 0.85% 0.52 Gy ≡ 1.45%
D95% Vol PTV 34.09 Gy ≡ 94.7% 33.84 Gy ≡ 94% 33.05 Gy ≡ 91.8% 32.95 Gy ≡ 91.54% 32.33 Gy ≡ 89.8%Radiation Oncology 2009, 4:48 http://www.ro-journal.com/content/4/1/48
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tion-therapy (AMRT) paradigm is capable of creating
conformal treatment plans, comparable to other IMRT
techniques. A reduction of treatment time by ~50% was
observed with slightly lower number of MU's for AMRT
[42].
Finally, Otto introduced a single arc rotation paradigm
increasing treatment efficiency by reducing delivery time
to 1.5-3 min which is in the range of what we report in this
evaluation. The report was focused on the theoretical
basis and technical details of the approach [22] but for a
single head-and-neck patient case discussed in his manu-
script he reported a treatment time of 107s for VMAT vs.
426s for IMRT with identical dose rate settings.
Palma et al. compared an early prototype of Varian's Rap-
idArc (Varian Medical Systems, Palo Alto, CA) technique
with 3D-CRT and fixed field dynamic IMRT for prostate
cancer. On a predominantly spherical target, they
reported, similar to our results, a higher treatment effi-
ciency for VMAT (491 MU constant dose rate/454 MU var-
iable dose rate) vs. 789 with IMRT as well shorter
treatment times [16], though the absolute level of MU was
higher in their series than in our comparison, reflecting an
earlier development stage of both modalities. IMRT and
VMAT provided better dose distributions than 3D-CRT. A
comparison of non-PTV tissue was not performed and can
therefore not be assessed.
The most recent report was provided by Cozzi et al. using
an improved version of the RapidArc prototype but with
focus on a larger PTV (cervix uteri). They reported a simi-
lar PTV coverage of VMAT (single rotation, variable dose
rate: up to 600 MU/Min) and IMRT (sliding window, 5
beams, fixed dose rate: 300 MU/min) with improved
homogeneity, better conformity and a major reduction of
OAR irradiation. Our results showed identical homogene-
ity for IMRT and VMAT but higher conformity of the IMRT
approach. Although a detailed comparative analysis of the
two series is not possible, this difference is most likely a
consequence of the higher number of incident beams -
and possibly more modulation - used in our comparison.
The different geometry of the PTV might also factor in
(PTV encompassing pelvic nodes only in their series vs.
pelvic and inguinal nodes in ours). Cozzi et al. reported
VMAT delivery with less than 2 min delivery time and less
than 245 MU/fraction. A direct comparison of IMRT and
VMAT to our situation was not possible due to the fact
that we used a step-and-shoot IMRT with 9 beams and a
dose rate of 600 MU/min.
While the relative merit of the different modulation
approaches with regard to PTV coverage and OAR sparing
cannot finally be assessed, the constant reduction in treat-
ment time and MU used for all approaches has now
reached a level at which any further discussion about det-
rimental effects of treatment protraction [37,38,41] or sec-
ondary tumors due to the higher primary number of MU
necessary for modulated therapy [22,43] is futile.
Conclusion
VMAT is an efficient treatment modality for large and
moderately complex pelvic targets already in its initial
developmental implementation. While in this situation
dose homogeneity and high dose conformity approach
that of highly modulated fixed beam IMRT, treatment
times and MU are further reduced. Further investigations
will show how efficient VMAT can handle other target vol-
umes and evaluate the delivery accuracy of this complex
treatment technique with multiple dynamical changes
during rotation.
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